Qyuns Therapeutics Co., Ltd. (QYUNS-B) has filed its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 31 August 2026, confirming a stable capital structure and continued compliance with Hong Kong Stock Exchange (HKEX) public-float requirements.
The company’s authorised share capital remained unchanged at RMB 227.07 million, comprising 227.07 million H-class ordinary shares with a par value of RMB 1.00 each.
Issued share data also showed no movement during the month: • Issued shares (excluding treasury shares): 223.37 million • Treasury shares: 3.70 million • Total issued shares: 227.07 million
QYUNS-B confirmed that the public float continues to meet the HKEX Initial Prescribed Threshold of 25% of issued H-shares.
During August, the company reported no new share options, warrants, convertible instruments, or other equity-linked agreements. There were likewise no repurchases, cancellations, or changes related to treasury stock. No Hong Kong Depositary Receipts are outstanding.
The filing, dated 4 September 2026, was signed by Board Secretary and Joint Company Secretary Hu Yanbao, who attested that all regulatory and listing-rule requirements have been satisfied.